GM1 Is Cytoprotective in GPR37-Expressing Cells and Downregulates Signaling

Int J Mol Sci. 2021 Nov 27;22(23):12859. doi: 10.3390/ijms222312859.

Abstract

G-protein-coupled receptors (GPCRs) are commonly pharmacologically modulated due to their ability to translate extracellular events to intracellular changes. Previously, studies have mostly focused on protein-protein interactions, but the focus has now expanded also to protein-lipid connections. GM1, a brain-expressed ganglioside known for neuroprotective effects, and GPR37, an orphan GPCR often reported as a potential drug target for diseases in the central nervous system, have been shown to form a complex. In this study, we looked into the functional effects. Endogenous GM1 was downregulated when stably overexpressing GPR37 in N2a cells (N2aGPR37-eGFP). However, exogenous GM1 specifically rescued N2aGPR37-eGFP from toxicity induced by the neurotoxin MPP+. The treatment did not alter transcription levels of GPR37 or the enzyme responsible for GM1 production, both potential mechanisms for the effect. However, GM1 treatment inhibited cAMP-dependent signaling from GPR37, here reported as potentially consecutively active, possibly contributing to the protective effects. We propose an interplay between GPR37 and GM1 as one of the many cytoprotective effects reported for GM1.

Keywords: GM1; GPCR; GPR37; Parkinson’s disease; cytoprotection; orphan receptor.

MeSH terms

  • Animals
  • Cytoprotection
  • Down-Regulation
  • G(M1) Ganglioside / pharmacology*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • HEK293 Cells
  • Humans
  • Mice
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / metabolism
  • Neuroblastoma / pathology
  • Neuroprotective Agents / pharmacology*
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism*
  • Signal Transduction

Substances

  • GPR37 receptor, human
  • Gpr37 protein, mouse
  • Neuroprotective Agents
  • Receptors, G-Protein-Coupled
  • G(M1) Ganglioside